As the OWCP longs wait for the next crazy run, I thought I’d dive in a bit and see what caused other biotechs to run hard. Stocks like AXIM, CNBX, GWPH, and NTRP to name a few. Purely because of alphabetical order, let’s…

After the trading day on Tuesday, April 4th, OWCP released a Form 8K to update it’s shareholders. As usual, there was more good news in which to reassure us all that the share price should absolutely keep rising to several dollars in the…

Anybody who has followed OWCP since the initial buzz back in late September and early October knows they’ve had several BIG runs, followed by nearly as many big retraces/consolidation periods. It’s been normal and quite frankly, expected. Many will tell you it’s quite…

The Form 8-K that was released after the market closed on Friday, February 24th, was ohhhhh, so beautiful. It’s really what many of us were waiting for – at least the IRB Approval part. I’ll be honest, I didn’t even know “NIH Registry”…

We’ve been saying for months that OWCP was grossly undervalued considering everything they have in the pipeline. The go-to comparative “piece of evidence” to support my claim is the fact that AstraZeneca sold off its troubled Psoriasis drug, which was linked to suicide…

OWCP has taken a hit like most of the Marijuana sector.  Why?  I don’t know.  Stoners want to pull their cash because somebody (incorrectly) said that the market would crash if Trump was elected?  (P.S. It’s been Green the last two days since…

Upon the News Release on October 20th, 2016, OWCP has reached a new 52-week high of $0.18 (as of 16 minutes into the trading day). The headline reads, “OWC Pharmaceutical Research Corp Completes Development of Its Medical Cannabis Sublingual Tablet”. OWC Pharmaceutical Research…

Eye catching headline, right?  Seriously though.  We have yet another eye opening comparison as “evidence” that $2.50/share is not impossible.  Yes, a stock that’s trading at $0.0531/share as of October 17th, 2016 has the potential to reach $2.50 (or beyond).  The question is:…

OWC Pharmaceutical Research Corp. (OTCQB: OWCP) conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. Just after the closing bell on Friday, October 14th, 2016, OWCP released an 8-K (see it…